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O S T E O A R T H R I T I S
Targeting cartilage EGFR pathway for  
osteoarthritis treatment
Yulong Wei1,2,3, Lijun Luo2, Tao Gui1, Feifan Yu4, Lesan Yan2, Lutian Yao1, Leilei Zhong1, 
Wei Yu1,3, Biao Han5, Jay M. Patel1,6, Jessica F. Liu2, Frank Beier7, Lawrence Scott Levin1, 
Charles Nelson1, Zengwu Shao3, Lin Han5, Robert L. Mauck1,2,6, Andrew Tsourkas2,  
Jaimo Ahn1,8, Zhiliang Cheng2*, Ling Qin1*
Osteoarthritis (OA) is a widespread joint disease for which there are no disease-modifying treatments. Previously, 
we found that mice with cartilage-specific epidermal growth factor receptor (EGFR) deficiency developed accelerated 
knee OA. To test whether the EGFR pathway can be targeted as a potential OA therapy, we constructed two 
cartilage-specific EGFR overactivation models in mice by overexpressing heparin binding EGF-like growth factor 
(HBEGF), an EGFR ligand. Compared to wild type, Col2-Cre HBEGF-overexpressing mice had persistently enlarged 
articular cartilage from adolescence, due to an expanded pool of chondroprogenitors with elevated proliferation 
ability, survival rate, and lubricant production. Adult Col2-Cre HBEGF-overexpressing mice and Aggrecan-CreER 
HBEGF-overexpressing mice were resistant to cartilage degeneration and other signs of OA after surgical destabi-
lization of the medial meniscus (DMM). Treating mice with gefitinib, an EGFR inhibitor, abolished the protective 
action against OA in HBEGF-overexpressing mice. Polymeric micellar nanoparticles (NPs) conjugated with trans-
forming growth factor– (TGF), a potent EGFR ligand, were stable and nontoxic and had long joint retention, 
high cartilage uptake, and penetration capabilities. Intra-articular delivery of TGF-NPs effectively attenuated 
surgery-induced OA cartilage degeneration, subchondral bone plate sclerosis, and joint pain. Genetic or pharma-
cologic activation of EGFR revealed no obvious side effects in knee joints and major vital organs in mice. Together, 
our studies demonstrate the feasibility of using nanotechnology to target EGFR signaling for OA treatment.
INTRODUCTION
Osteoarthritis (OA) is the most common chronic condition of the 
joints, affecting 303 million people globally in 2017 (1). As a joint 
degenerative disease, it is primarily characterized by destruction of 
articular cartilage but is often accompanied by subchondral bone 
thickening, osteophyte formation, synovial inflammation, and hyper-
trophy of the joint capsule (2). Posttraumatic OA develops after 
joint injury and causes an acute form of cartilage degeneration. Pa-
tients with OA experience pain and disability, for which there are 
neither cures nor disease-modifying treatments.
The outermost superficial layer of articular cartilage is the first 
line of defense against OA initiation. Distinct from other layers of 
articular cartilage (transitional, middle, and calcified zones), this two- 
to four-cell-thick superficial zone has distinct biologic and mechan-
ical functions, such as producing lubricant proteins, harboring 
chondroprogenitors, resisting shear stresses, and serving as a gliding 
surface (3). In OA, degenerative changes are initiated with cellular 
disorganization and irregular surface of the superficial layer (4–6).
The epidermal growth factor receptor (EGFR) is one of the most 
well-studied signaling pathways. Upon activation by its ligands, 
EGFR dimerizes with itself or other members of the EGFR family to 
modulate a variety of cellular functions, such as proliferation, sur-
vival, adhesion, migration, and differentiation (7). Mice lacking 
EGFR activity specifically in cartilage (Col2-Cre) have fewer super-
ficial chondrocytes, less secretion of boundary lubrication, and 
weak mechanical strength at the cartilage surface than their wild-
type (WT) siblings (8). With a defective articular cartilage surface, 
these mice develop markedly accelerated knee OA during aging or 
after OA injury (8, 9). Mig6 is a negative feedback inhibitor of EGFR 
(10). Consistently, mice with Mig6 deficiency in cartilage or limb 
bud mesenchyme display thickened articular cartilage with a drasti-
cally increased number of superficial chondrocytes at a young age 
(11–13). Together, these lines of evidence suggest that the EGFR 
pathway is critical for maintaining homeostasis of the superficial 
layer of articular cartilage.
We hypothesized that targeting the EGFR pathway could be an 
effective OA therapy. To test this, we designed a two-pronged 
approach. First, we genetically enhanced EGFR activity by adopting 
a Rosa-diphtheria toxin receptor (DTR) model that is normally used 
for cell ablation (14). Originally identified as a receptor for bacterial 
diphtheria toxin, DTR was later found to be human full-length hep-
arin binding EGF-like growth factor (HBEGF) (15), a ligand for 
EGFR. Human HBEGF shares 81% sequence identity with the 
mouse ortholog. Breeding Rosa-DTR mice with cartilage-specific 
Col2-Cre or Aggrecan-CreER mice allowed us to study the effect of 
cartilage-specific EGFR overactivation on OA progression. Second, 
we developed an advanced nanoparticle (NP)–based system for the 
local delivery of an EGFR ligand, transforming growth factor– 
(TGF), into knee cartilage. Because TGF, the most highly ex-
pressed EGFR ligand in mouse cartilage (8), has a short life span of 
20 min in the circulation (16), it is not feasible to use TGF directly 
1Department of Orthopaedic Surgery, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA 19104, USA. 2Department of Bioengineering, School 
of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 
19104, USA. 3Department of Orthopaedics, Union Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan 430022, China. 4Alphathera 
LLC, Philadelphia, PA 19146, USA. 5School of Biomedical Engineering, Science and Health 
Systems, Drexel University, Philadelphia, PA 19104, USA. 6Translational Musculoskeletal 
Research Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 
19104, USA. 7Department of Physiology and Pharmacology, Schulich School of Medicine 
and Dentistry, University of Western Ontario, London, Ontario N6A 5C1, Canada. 
8Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI 48104, USA.
*Corresponding author. Email: qinling@pennmedicine.upenn.edu (L.Q.); zcheng@seas.
upenn.edu (Z.C.)
Copyright © 2021 




for the Advancement 
of Science. No claim  














Wei et al., Sci. Transl. Med. 13, eabb3946 (2021)     13 January 2021
S C I E N C E  T R A N S L A T I O N A L  M E D I C I N E  |  R E S E A R C H  A R T I C L E
2 of 14
as an OA drug. Recently, NP-based targeted drug delivery has been 
pursued in the treatment of OA (17–19). A strength of these delivery 
systems is the prolonged retention of drugs in the joints, thus low-
ering the overall therapeutic dose required and reducing off-target 
toxicity and side effects. To increase the retention and minimize the 
leakage of TGF from the joint space, we synthesized TGF-NPs by 
conjugating TGF onto the surfaces of polymeric micellar NPs. We 
then characterized the properties of these TGF-NPs in the joint 
tissue and performed a proof-of-principle study by testing their 
efficacy in attenuating OA progression in a mouse injury model.
RESULTS
Overexpression of HBEGF in chondrocytes leads to  
cartilage enlargement
To target the EGFR pathway in cartilage, we generated Col2-Cre 
Rosa- DTR mice [Col2-Cre Rosa-HBEGF (HBEGF OverCol2) mice]. 
These mice had similar body weight and body length as WT mice 
(fig. S1). Western blots (Fig. 1A) and immunohistochemistry (IHC; 
fig. S2) confirmed that there was increased HBEGF in chondro-
cytes, leading to EGFR activation as shown by elevated phospho- 
EGFR (p-EGFR) and phospho–extracellular signal–regulated kinase 
(p-ERK) amounts (Fig. 1A). HBEGF OverCol2 mice at 5 and 12 months 
of age displayed normal knee joints (Fig. 1B) without gross abnor-
malities, such as osteophytes or synovitis (fig. S3). Long bone structure, 
including subchondral trabecular bone, subchondral bone plate (SBP), 
and metaphyseal trabecular bone, was also not affected (fig. S4).
The most obvious change in the HBEGF OverCol2 skeleton is car-
tilage. At 1 month of age, its growth plate was modestly expanded 
by 16%, mainly due to the elongation of the proliferative zone 
(Fig. 1, C to E). On the contrary, its hypertrophic zone was shrunk. 
At 5 months of age, the expansion of growth plate was more obvi-
ous (2.41-fold). Similar expansion was also observed in articular 
cartilage (23 and 34% increases in total cartilage thickness at 1 and 
Fig. 1. Overexpression of HBEGF in chondrocytes expands mouse growth plate and articular cartilage without affecting the gross appearance of knee joints. 
(A) Western blot of HBEGF and EGFR downstream signals (p-EGFR and p-ERK) in articular cartilage chondrocytes derived from 5-month-old HBEGF OverCol2 mice. n = 3 
independent experiments. (B) Safranin O/Fast Green staining of knee joints from 5- or 12-month-old HBEGF OverCol2 and control littermates (WT). M, month. Scale bars, 
1 mm. n = 3 mice per group. (C) Safranin O/Fast Green staining of tibial growth plate in WT and HBEGF OverCol2 mice at 1 and 5 months of age. Scale bar, 200 m. (D) The 
thicknesses (Th.) of the proliferative zone (PZ) and hypertrophic zone (HZ) in the growth plate of 1-month-old mice. n = 5 mice per group. (E) The growth plate thickness 
(GP Th.) quantified from 1- and 5-month-old mice. n = 5 mice per group. (F) Safranin O/Fast Green staining of articular cartilage in WT and HBEGF OverCol2 knee joints at 
1 and 5 months of age. Scale bar, 200 m. (G) Average thicknesses of the uncalcified zone (Uncal. Th.), calcified zone (Cal. Th.), and total tibial articular cartilage quantified 
from 1- and 5-month-old mice. n = 8 mice per group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc analysis. Data are presented as 
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5 months of age, respectively) with a major change in uncalcified 
cartilage but not in calcified cartilage (Fig. 1, F and G).
EGFR overactivation expands the chondroprogenitor pool
The superficial layer contains chondroprogenitors responsible for 
forming cells in the rest of articular cartilage during development 
(20). Our previous study showed that EGFR inactivation in chon-
drocytes (Col2-Cre CKO) leads to fewer superficial chondrocytes 
(8). In WT joints, the number of chondrocytes in the superficial 
zone declined by 39% during cartilage maturation (Fig. 2, A and B). 
This decline did not occur in HBEGF OverCol2 mice, which exhibited 
a 1.79-fold increase in superficial chondrocytes compared to WT at 
5 months of age (Fig. 2, A and B). This was accompanied by en-
hanced Ki67 and proteoglycan 4 (PRG4) staining and reduced termi-
nal deoxynucleotidyl transferase deoxyuridine triphosphate nick end 
labeling (TUNEL) staining (Fig. 2, C and D) in HBEGF OverCol2 mice, 
suggesting that constitutive overactivation of EGFR signaling pro-
motes proliferation, survival, and lubricant synthesis in chondrocytes.
5-Ethynyl-2′-deoxyuridine (EdU) labels cells undergoing prolif-
eration. At 1 week of age, 46% of periarticular cells in epiphyseal 
cartilage, the site for future articular cartilage, were labeled in WT 
mice (Fig. 2, E and F). Three weeks later when articular cartilage is 
established, 27% of chondrocytes (most of them in uncalcified car-
tilage) were still labeled by EdU, indicating that many proliferative 
chondrocytes are slow-cycling cells, i.e., chondroprogenitors. HBEGF 
OverCol2 mice had more EdU+ cells than WT mice at 4 weeks of age 
(Fig.  2,  E  and  F). After dissection and digestion, 5-month-old 
HBEGF OverCol2 cartilage formed 1.96-fold more colony-forming 
unit fibroblast (CFU-F) colonies than WT cartilage in culture 
(Fig. 2, G and H). In addition, progenitors from HBEGF OverCol2 
cartilage grew much quicker than those from WT (Fig. 2I) and were 
resistant to tumor necrosis factor– (TNF)–induced apoptosis 
(Fig. 2J). Meanwhile, synovial mesenchymal progenitors were not 
affected (fig. S5). Together, our in vivo and in vitro data demon-
strate that HBEGF overexpression produces more chondroprogen-
itors in articular cartilage with superior proliferation and survival 
abilities.
When subjected to chondrogenic differentiation, progenitors 
from HBEGF OverCol2 cartilage expressed more Prg4 but less carti-
lage matrix (Aggrecan, Col2a1, and Col10a1) and protease (Mmp13) 
markers (Fig. 2K). They differentiated into Alcian blue–positive 
cartilage, albeit the staining intensity was less than WT (Fig. 2L). 
These in vitro data indicate that overexpression of HBEGF modestly 
decreases chondrogenic differentiation; however, immunostaining 
confirmed that proteoglycan, type II collagen, type X collagen, and 
MMP13 (fig. S6) amounts were not altered in HBEGF OverCol2 car-
tilage, suggesting that overactivation of EGFR signaling does not 
negatively affect cartilage components in vivo.
As a transmembrane protein, HBEGF is cleaved by a sheddase 
and released from the cell membrane for paracrine and systemic 
actions (21). Because EGFR is important for the development and 
homeostasis of multiple organs, a concern is raised about possible 
side effects of constitutively expressing HBEGF. However, we did 
not observe p-EGFR in major organs, such as heart, liver, spleen, 
lung, kidney, and brain from adult HBEGF OverCol2 mice (fig. S7A). 
Endogenous EGFR and HBEGF were also not altered (fig. S7A). 
The morphology of these vital organs remained the same as WT 
mice at 5 and 12 months of age (fig. S7B), indicating no substantial 
side effects of cartilage-specific HBEGF overexpression.
EGFR overactivation attenuates OA progression
Next, we sought to study the effect of HBEGF overexpression on 
OA progression induced by surgical destabilization of the medial 
meniscus (DMM) (Fig. 3A). Two months after surgery, WT knees 
started to lose proteoglycan and exhibit fibrillation at the cartilage 
surface (Fig. 3, B and C). At 4 months after surgery, WT knees dis-
played severe cartilage erosion beyond the tidemark, accompanied 
by uneven cartilage surface or clefts. In contrast, knees in HBEGF 
OverCol2 mice showed only a minor loss in proteoglycan content 
2 months after DMM surgery. Two months later, the articular sur-
face was still intact, although cartilage was thinner than that in 
sham knees. Quantifying OA severity at 4 months after surgery 
revealed that overexpression of HBEGF reduced Mankin score 
from 10.0 to 2.1 at this stage (Fig. 3C). These data provided in vivo 
evidence that overactivation of EGFR could protect cartilage from 
degeneration upon OA-inducing insults.
To eliminate the developmental effect in HBEGF OverCol2 
mice, we next constructed an inducible model Aggrecan-CreER DTR 
(HBEGF OverAgcER). These mice had normal articular cartilage 
before injury since tamoxifen was injected immediately before 
DMM surgery (Fig.  3D). IHC confirmed higher amounts of 
HBEGF and p-EGFR in articular cartilage of HBEGF OverAgcER 
compared to the sham knees 1 month after induction (fig. S8). 
Four months after DMM surgery, whereas WT mice developed 
late OA with most cartilage eroded, HBEGF OverAgcER maintained 
relatively intact articular cartilage with a low Mankin score of 2.5 
(Fig. 3, E and F). Our prior study demonstrated that nanoinden-
tation of the cartilage surface is a sensitive method to detect early 
OA in mice (22). In line with this, the surface indentation modulus 
Eind was drastically reduced by 67% in WT cartilage at 1 month 
after DMM but remained unchanged in HBEGF OverAgcER mouse 
knees (Fig. 3G), suggesting that overexpressing HBEGF in adult 
cartilage preserves the mechanical functions of the cartilage surface 
after OA injury.
HBEGF binds and signals through EGFR as well as another EGFR 
family member, ErbB4 (23). To study whether EGFR mediates the 
action of HBEGF on cartilage in vivo, we treated HBEGF OverAgcER 
mice and WT controls with the EGFR-specific inhibitor gefitinib 
(24) once every other day for 2 months after tamoxifen induction 
and DMM surgery. Similar to our previous data (25), gefitinib mod-
erately accelerated OA progression in WT DMM knees, increasing 
Mankin score from 6.5 to 9.8 (Fig. 4, A and B). Gefitinib completely 
abolished the protective effect of HBEGF OverAgcER on articular car-
tilage after DMM surgery, leading to marked cartilage erosion with 
an elevated Mankin score of 9.0. DMM mainly reduced the thick-
ness of uncalcified cartilage, resulting in 38 and 74% decreases in 
vehicle- and gefitinib-treated WT mice, respectively (Fig. 4C). In 
HBEGF OverAgcER mice, although DMM alone did not alter the car-
tilage thickness, cotreatment with gefitinib greatly lessened the 
thicknesses of uncalcified and total cartilage by 75 and 59%, respec-
tively (Fig. 4C). Furthermore, the von Frey behavioral pain test 
indicated that HBEGF OverAgcER mice developed a similar degree of 
pain as WT mice at 1 week after DMM but quickly recovered to 
baseline as sham mice, suggesting that overexpressing HBEGF also 
has functional benefits (Fig. 4D). However, gefitinib abolished this 
effect. We did not detect any effect of this inhibitor on sham knees 
from WT or HBEGF OverAgcER mice. Therefore, our results indicated 
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Synthesis and characterization of TGF-NPs
Cartilage expresses TGF and other EGFR ligands (8); however, the 
above mouse studies indicated that endogenous EGFR ligand ex-
pression is not sufficient to protect cartilage against OA. To activate 
EGFR for OA treatment, we chose one of the most potent EGFR li-
gands, TGF (26), as an activator. However, TGF is not stable in 
Fig. 2. Overexpression of HBEGF increases chondroprogenitors in articular cartilage. (A) Hematoxylin and eosin staining of femoral articular cartilage from WT and 
HBEGF OverCol2 mice at 1 and 5 months of age. Scale bar, 50 m. (B) Chondrocyte numbers (CH) in superficial zone (SZ), transition and middle zones (TZ + MZ), calcified 
zone (CZ), and entire femoral articular cartilage quantified at 1 and 5 months of age. n = 8 mice per group. (C) Immunostaining of Ki67, TUNEL, and PRG4 in tibial articular 
cartilage of 5-month-old WT and HBEGF OverCol2 mice. Scale bar, 50 m. (D) The percentages of Ki67+, TUNEL+, and Prg4+ cells within articular cartilage were quantified. 
n = 8 mice per group. (E) Long-term EdU labeling of slow-cycling cells in the tibial articular cartilage of HBEGF OverCol2 mice. Mice received daily EdU injections from post-
natal days 4 to 6, and their joints were harvested at 1 and 4 weeks of age for EdU staining. Dashed lines outline periarticular layer (1 week of age) and articular cartilage 
(4 weeks of age) for analysis. Scale bar, 100 m. (F) Quantification of EdU+ cells in outlined regions. n = 5 mice per group. (G) CFU-F assay using chondrocytes dissociated 
from mouse knee joints from 5-month-old WT and HBEGF OverCol2 mice. Scale bar, 0.5 cm. (H) Quantification of CFU-F frequency. n = 5 mice per group. (I) Proliferation of 
primary chondroprogenitors from 5-month-old WT or HBEGF OverCol2 knee joints. Cells were seeded at the same density on day 0, and their numbers were counted every 
other day. n = 5 independent experiments. (J) Apoptosis assay of primary chondrocytes from 5-month-old WT and HBEGF OverCol2 knee joints. Cells were incubated with 
or without TNF (25 ng/ml) or vehicle (Veh; PBS) for 2 days before analysis. n = 5 independent experiments. (K) qRT-PCR analyzes the relative gene expression in chondro-
progenitors from WT and HBEGF OverCol2 knee joints undergoing 2 weeks of chondrogenic differentiation. n = 3 independent experiments. (L) Alcian blue staining of 
chondroprogenitors after 2 weeks of chondrogenic differentiation. Scale bar, 200 m. n = 3 independent experiments. Statistical analysis was performed using two-way 
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the circulation, and direct injection of it into knee joints suffers 
from rapid clearance due to its low molecular weight (5.6 kDa). To 
overcome this challenge, we engineered an NP delivery system to 
prolong the retention of active TGF in the knee joint. Briefly, 
bacteria-expressed human TGF were synthesized and site-specifically 
labeled at the C terminus with a constrained alkyne, dibenzocy-
clooctyne (DBCO), via sortase-tag–expressed protein ligation (27, 28). 
TGF-NPs were then prepared via copper-free click chemistry, 
by simply mixing TGF-DBCO with azide-functionalized NPs 
(Fig. 5A). Azide-functionalized NPs were made from 55 mole 
percent (mol %) poly(ethylene glycol)-polycaprolactone (PEG-PCL)/ 
20 mol % poly[l-lysine-block-poly(-caprolactone)] (PLL-PCL)/ 
25 mol % 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- 
[azido(polyethylene glycol)-5000] (DSPE-PEG5K-N3) using the film 
hydration method.
TGF-NPs resembled spheres with a hydrodynamic diameter 
of 25.93 nm (Fig. 5B). Because NP surface charge could be adjusted 
to augment the interaction between 
the therapeutic agents and the anionic 
glycosaminoglycans in the cartilage, 
the cationic diblock copolymer PLL-
PCL was synthesized (fig. S9) and intro-
duced into the PEG-PCL NPs to reduce 
their surface charge from −4.2 to −1 mV 
(Fig. 5C). After the conjugation of TGF, 
the surface charge of TGF-NPs be-
came more negative, mostly due to the 
negatively charged TGF. However, the 
magnitude of the surface charge of TGF- 
NPs was still reduced in NPs containing 
PLL-PCL. For example, the surface charges 
of TGF-NPs in the presence and ab-
sence of PLL-PCL were −13.7 and −19.4 mV, 
respectively. We next characterized sta-
bility, cytotoxicity, and specificity of 
newly synthesized TGF-NPs. We did 
not detect any change in the hydrody-
namic diameter of TGF-NPs in water 
for at least 1 week (Fig. 5D) or in bovine 
synovial fluid for 24 hours (Fig. 5E). 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide] assay 
showed that TGF-NP treatment (up to 
10 M TGF content) for 24 hours did 
not affect the viability of mouse primary 
chondrocytes (Fig. 5F). Western blot 
demonstrated that TGF-NPs activated 
EGFR downstream target ERK as po-
tently as free TGF, whereas Ctrl-NPs 
(NP with no TGF conjugation) had no 
such effect (Fig. 5, G and H). In addi-
tion, similar to free TGF, TGF-NPs 
changed chondrocytes from a polygonal 
cell shape to a more spindle cell shape 
after 2 days of treatment (fig. S10). Using 
fluorescent rhodamine-labeled TGF-NPs, 
we found that TGF-NPs bound to the 
surface of primary chondrocytes in a 
TGF-specific manner (Fig. 5I). More-
over, in human articular cartilage explants, TGF-NPs activated 
ERK (fig. S11A); reduced the expression of chondrocyte markers 
Sox9, Aggrecan, and Col2a1; and elevated the expression of lubri-
cant Prg4, cyclin gene Ccnd1, and proteinase MMP13 (fig. S11B). 
These results are consistent with previous studies reporting the 
effect of TGF on rodent and bovine cartilage explants (29). 
TGF-NPs decreased the expression of Adamts5, the major aggreca-
nase, in human cartilage, which is also in line with a previous report 
studying TGF actions on rat chondrocytes (30). Together, our data 
demonstrate that TGF-NPs are stable, nontoxic, and functional.
TGF-NP cartilage uptake, penetration, and joint retention
Human knee articular cartilage is about 2 to 4 mm thick, and the 
superficial layer makes up 10 to 20% of cartilage thickness (31). To 
increase cartilage retention and to penetrate deeper into the cartilage, 
we doped cationic PLL-PCL into the NPs to reduce their surface 
charge. Using a near-infrared fluorescence probe IRDye 800CW as 
Fig. 3. Overexpressing HBEGF in articular cartilage delays OA progression. (A) Schematic showing the study 
protocol of WT and HBEGF OverCol2 mice with DMM surgery at 3 months of age. H indicates time points when histology 
was performed. (B) Safranin O/Fast Green staining of DMM and sham joints at the medial site from 5- and 7-month-old 
WT and HBEGF OverCol2 mice. Low: low-magnification image; high: high-magnification image of the yellow boxed 
area above. Scale bars, 200 m. (C) The OA severity was measured by Mankin score. n = 8 mice per group. (D) Sche-
matic showing the study protocol of WT and HBEGF OverAgcER mice with tamoxifen (Tam) injections and DMM surgery 
at 3 months of age. (E) Safranin O/Fast Green staining of WT and HBEGF OverAgcER DMM and sham joints at the medial 
site from mice 7 months of age. Scale bars, 200 m. (F) The OA severity was measured by Mankin score. n = 8 mice per 
group. (G) Nanoindentation assay was performed on the femoral cartilage surface at 1 month after surgery. Eind, 
modulus. n = 4 to 5 mice per group. Statistical analysis was performed using two-way ANOVA with Tukey’s post hoc 
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a label, we found that bovine cartilage explants took up much more 
PLL-PCL–doped TGF-NPs than non–PLL-PCL–doped TGF-NPs 
or TGF-DBCO after a 24-hour incubation (fig. S12). To study 
penetration, we labeled TGF-NPs and TGF-DBCO with rhodamine. 
TGF-DBCO and non–PLL-PCL–doped TGF-NPs only accumu-
lated at the cartilage surface but did not penetrate deep inside the 
cartilage over a 6-day culture period (Fig. 6, A and B, and fig. S13, A 
to D). PLL-PCL–doped TGF-NPs efficiently bound to the surface 
of bovine cartilage explants at day 2 and gradually penetrated inside 
by at least 1 mm by day 6 (Fig. 6, A and B, and fig. S13, E and F). 
Quantitative analysis of the fluorescence images revealed that PLL-
PCL–doped TGF-NPs exhibited more than a 4.76-fold improvement 
in cartilage penetration at day 6 compared with non–PLL-PCL–
doped TGF-NPs (Fig. 6C) with an estimated diffusivity of 1.1 m2/s. 
This result demonstrated the improved cartilage penetration and 
accumulation of TGF-NPs with PLL-PCL.
Next, we directly injected TGF-NPs or TGF-DBCO labeled 
with IRDye 800CW into the knee joint to study retention under 
healthy and OA conditions (Fig. 6D). DMM was performed on the 
joints 2 months before injection to mimic OA. After a single injec-
tion, the fluorescence signal in joints injected with TGF-NPs was much 
higher than those injected with TGF-DBCO at all time points, 
indicating the increased retention of TGF-NPs (Fig. 6E). Quantitative 
analysis of fluorescence images showed that TGF-NPs in OA joints 
were retained even longer than those in healthy joints (Fig. 6F).
We also examined the biodistribution of TGF-NPs in internal 
organs, blood, and joint components. At 24 hours after injection, 
fluorescent signals were detected on the cartilage surfaces of the pa-
tella, femoral condyles, and the tibial plateau, as well as on meniscus 
(fig. S14, A and B). TGF-NPs were mainly accumulated in liver 
and kidneys, but no signal was detected in the blood, heart, and 
spleen, indicating that NPs can be cleared quickly from circulation. 
One month later, there were no TGF-NPs left in liver and kidney 
(fig. S14, C and D).
TGF-NP rescue of OA cartilage degeneration after  
DMM surgery
To test their therapeutic effect on OA, we injected TGF-NPs into 
mouse knee joints after DMM once every 3 weeks. Control groups 
include knee joints injected with phosphate-buffered saline (PBS), 
TGF-DBCO, and Ctrl-NPs (NP with no TGF conjugation). In 
line with our previous findings (8), EGFR activity, as indicated by 
p-EGFR, was decreased in PBS-treated articular cartilage after 
DMM (Fig. 7A). Injections of TGF-NPs, but not TGF-DBCO or 
Ctrl-NPs, successfully elevated cartilage EGFR activity to that of the 
sham group (Fig. 7A). At 2 and 3 months after surgery, both the 
Fig. 4. The protective action of HBEGF overexpression on articular cartilage during OA development is EGFR dependent. (A) Safranin O/Fast Green staining of 
vehicle- and gefinitib (Gef)–treated WT and HBEGF OverAgcER knee joints at the medial site 2 months after surgery. Low: low-magnification image; high: high-magnification 
image of the yellow boxed area above. Scale bars, 200 m. (B) The OA severity was measured by Mankin score. n = 8 mice per group. (C) Average thicknesses of uncalcified 
(Uncal. Th.) and total (Total Th.) cartilage quantified at 2 months after surgery. n = 8 mice per group. (D) von Frey assay was performed at 0, 1, 2, 4, and 8 weeks after sur-
gery. PWT, paw withdrawal threshold. n = 8 mice per group. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc analysis for (D) and two-way 
ANOVA with Tukey’s post hoc analysis for (B) and (C). Data are presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 in (B) and (C). *P < 0.05 and ***P < 0.001 for 
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TGF-DBCO group and Ctrl-NP group displayed a similar pattern 
of cartilage degeneration, including erosion and surface fibrillation, 
similar to the PBS group (Fig. 7B). Mankin scores of these three 
control groups at 3 months after DMM were similarly around 
8.5 (Fig. 7C), mainly due to the reduction of uncalcified cartilage 
thickness (Fig. 7D). Knee joints in the TGF-NP group maintained 
cartilage integrity at 2 months after DMM and displayed minor 
signs of degeneration at 3 months after DMM (Fig. 7B). The Mankin 
scores at both 2 and 3 months were markedly decreased compared 
to control groups and their uncalcified zones were largely preserved 
(Fig. 7, C and D, and fig. S15). Similar results were also observed 
when TGF-NP injections started 1 month after DMM (to allow 
early OA develop) (fig. S16).
To understand the mechanism underlying the therapeutic effect 
of EGFR overactivation, we performed IHC of EGFR downstream 
targets in sham and DMM knees at 2 months after surgery of 
HBEGF OverCol2 mice and TGF-NP–injected WT mice (fig. S17). 
Consistent with the cartilage degeneration phenotype, DMM re-
duced the amounts of anabolic factors, such as p-ERK and PRG4, 
and increased the amounts of catabolic factors, such as MMP13 and 
ADAMTS5, in the articular cartilage. Overexpression of HBEGF or 
intra- articular injection of TGF-NP efficiently reversed those 
changes, resulting in similar staining patterns of those proteins 
between sham and DMM knees of these mice.
Subchondral bone sclerosis is a late OA symptom. Our previous study 
established a three-dimensional micro–computed tomography (3D 
Fig. 5. Preparation and characterization of TGF-NPs. (A) Schematic diagram of TGF-NPs. TGF-NPs were prepared by conjugating TGF onto polymeric micellar NPs 
via copper-free click chemistry. (B) Dynamic light scattering (DLS) measurements of TGF-NP hydrodynamic diameter (size) and representative image of TGF-NPs exam-
ined by transmission electron microscopy. Scale bar, 100 nm. (C) Zeta potential measurements of TGF-DBCO, PEG-PCL NPs with or without PLL-PCL, and TGF-NPs with 
or without PLL-PCL in 0.1× PBS (pH 7.4). PLL+ denotes the NPs that contain PLL-PCL, and PLL− denotes the NPs that do not contain PLL-PCL. n = 3 independent experi-
ments. (D) Stability of TGF-NPs in water was evaluated by monitoring DLS measurement of TGF-NP hydrodynamic diameter for up to 7 days. n = 3 independent exper-
iments. (E) Stability of TGF-NPs in bovine synovial fluid of knee joint was evaluated by monitoring DLS measurement of TGF-NP hydrodynamic diameter for up to 
24 hours. n = 3 independent experiments. (F) Cell viability of primary mouse chondrocytes after incubation with TGF-NPs at different concentrations. n = 3 independent 
experiments. (G) Western blot of EGFR downstream signal (p-ERK) in articular cartilage chondrocytes treated by vehicle (PBS), free TGF (15 ng/ml), Ctrl-NPs (i.e., no TGF 
conjugation), or TGF-NPs (15 or 100 ng/ml of TGF content). (H) Quantitative analysis of the relative protein amount (p-ERK/ERK) based on the images of Western blot 
as in (G). n = 3 independent experiments. (I) Confocal images of mouse primary chondrocytes treated with vehicle (PBS), TGF-NPs (10 nM TGF content), or TGF-NPs (10 
nM TGF content) in the presence of free TGF (100 g/ml). Scale bar, 50 m. n = 3 independent experiments. Statistical analysis was performed using one-way ANOVA 
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microCT) approach to accurately measure the thickness of SBP (9). 
Using this method, we confirmed that SBP thicknesses were elevated 
in PBS-treated, TGF-DBCO–treated, and Ctrl-NP–treated DMM 
knees relative to sham (Fig. 7, E and F). However, this increase was 
abolished in TGF-NP–treated DMM knees. Synovitis is another sign 
of OA (32). We observed thickening of the synovial lining layer and 
increased synovitis scores in DMM knees with PBS, TGF-DBCO, 
or Ctrl-NP treatment but not with TGF-NP treatment relative 
to sham (Fig. 7, G and H). Moreover, von Frey assay revealed that 
TGF-NP treatment attenuated OA-induced pain starting from 
2 weeks after surgery (Fig. 7I). Together, 
these results demonstrate a therapeutic 
effect of intra-articular delivery of EGFR 
ligand–conjugated polymeric micellar NP.
Last, we examined whether 2 months 
of intra-articular injections of TGF-NPs 
caused any side effects to several major 
internal organs or to overall joint struc-
ture in WT mice. As shown in fig. S18A, 
we did not detect any obvious morpho-
logic changes in heart, liver, spleen, lung, 
kidney, and brain between PBS-treated 
and TGF-NP–treated mice. Western 
blots indicated no change in EGFR 
activity in those organs after TGF-NP 
injections (fig. S18B). Liver and lung 
had the highest expression of EGFR 
and TGF, which were not affected by 
TGF-NP injections. Furthermore, the 
gross morphology of knee joints was 
not altered by 2 months of TGF-NP 
treatment (fig. S18C).
DISCUSSION
Previous studies from our group and 
others have demonstrated the impor-
tant role of EGFR signaling in the devel-
opment of articular cartilage and in OA 
progression (29). EGFR signaling can 
execute both anabolic and catabolic 
actions on cartilage chondrocytes; how-
ever, differences exist regarding how 
this signaling pathway may be best modu-
lated for OA treatment. In the present 
study, we first provide genetic evidence 
demonstrating that overactivation of 
EGFR signaling modestly thickens the 
articular cartilage and completely blocks 
OA progression after DMM surgery. 
Other joint tissues, such as bone, sy-
novium, and meniscus, appeared nor-
mal in mice up to 12 months of age and 
showed no pathological OA changes, 
such as osteophytosis and subchondral 
bone sclerosis, suggesting that EGFR sig-
naling could be precisely applied in vivo 
to fulfill its anabolic actions without in-
citing catabolic effects. We then provided 
proof-of-principle evidence that administration of TGF into mouse 
joints using an advanced NP delivery system is effective in attenuat-
ing DMM-induced OA initiation and development.
One mechanism underlying the therapeutic action of EGFR sig-
naling is that EGFR activation promotes the lubrication function of 
articular cartilage, particularly the expression of lubricant Prg4. In 
humans, loss-of-function PRG4 mutation results in camptodactyly– 
arthropathy–coxa vara–pericarditis syndrome with precocious joint 
failure (33). Mice lacking Prg4 display early OA (34). On the con-
trary, intra-articular treatment with recombinant PRG4 prevented 
Fig. 6. TGF-NPs exhibit full-length penetration of human-thickness bovine articular cartilage and extend 
residence time in both healthy and diseased knee joints. (A) Representative confocal microscopy images of a 
cross section of bovine cartilage explants incubated with rhodamine-labeled TGF-NPs with or without PLL-PCL or 
free TGF for 2, 4, and 6 days. Arrow indicates the diffusion direction. Scale bar, 200 m. (B) Quantitative analysis of 
TGF-NP penetration depth into bovine cartilage explants after 6-day incubation. n = 3 per group. (C) Quantitative 
analysis of area under the curve (AUC) based on fluorescence intensity profiles in (B). n = 3 per group. (D) Represent-
ative fluorescence images of healthy and OA mouse knee joints over 28 days after intra-articular injection of IRDye 
800CW–labeled TGF or TGF-NPs. (E) Quantitative analysis of time course fluorescence radiant efficiency within 
knee joints after intra-articular injection of IRDye 800CW–labeled TGF or TGF-NPs. n = 6 per group. (F) Quantitative 
analysis of area under the curve based on fluorescence intensity profile in (E). n = 6 per group. Statistical analysis was 
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cartilage degeneration in a rat OA surgery model (35). Delayed 
administration of teriparatide (Forteo), the recombinant human 
parathyroid hormone (1-34), was shown to have a chondro-regenerative 
effect, which correlated with increased Prg4 mRNA in mouse OA 
articular chondrocytes (36). In our previous study, we demonstrated 
that EGFR deficiency leads to reduced PRG4 amount in the articu-
lar cartilage and that TGF promotes Prg4 expression in bovine 
cartilage (8). In the current study, we 
found that EGFR overactivation, either 
by overexpressing HBEGF or adminis-
tration of TGF-NPs, preserved PRG4 
in articular cartilage, which is otherwise 
diminished in OA. Together, we believe 
that PRG4 plays a critical role in medi-
ating the chondroprotective action of 
EGFR signaling.
Currently, there are no disease- modifying 
drugs clinically approved for treating OA. 
Nonsteroidal anti-inflammatory agents 
have often been used for the short-term 
management of the pain symptoms in 
OA. More recently, several protein thera-
pies, such as insulin-like growth factor 
(IGF) (37) and fibroblast growth factor 
18 (38), have shown promise for OA 
treatment. However, intra-articular de-
livery of these therapeutic proteins has 
been largely limited by their rapid clear-
ance from the joint space and their low 
penetration into the dense, avascular 
cartilage matrix. Consistent with this, we 
also observed that intra-articular injec-
tion of free TGF had low joint reten-
tion and poor cartilage penetration and 
thus was ineffective in preventing OA 
development and progression. Because 
of its favorable pharmacokinetics, bio-
distribution, and specificity, NP-based 
drug delivery systems have been ex-
plored to improve drug delivery and 
therapeutic efficacy in OA treatment. 
For example, Geiger et al. (17) devel-
oped dendrimer-based nanocarriers to 
deliver IGF-1 to chondrocytes within 
joint cartilage. The dendrimer IGF-1 
could penetrate full-thickness bovine car-
tilage and enhance the efficacy of IGF-1 
in protecting both cartilage and bone in 
a rat surgical model of OA. Yan et al. 
(19) used NP-based small interfering 
RNA delivery to attenuate early inflam-
mation in OA development.
We have addressed the TGF delivery 
challenges by conjugating TGF onto 
nanometer-sized polymeric micellar NPs. 
Polymeric micellar NPs are nanoscopic 
core/shell structures formed by amphi-
philic block copolymers (39–41). Com-
pared to other drug nanocarriers (42), 
the polymeric NPs provide several advantages, including their rela-
tively small size and the use of similar formulations in different pre-
clinical and clinical studies. In this work, polymeric micellar NPs 
were prepared from biocompatible and biodegradable polymers 
including PEG-PCL, PLL-PCL, and pegylated phospholipids. PEG, 
PCL, PLL, and phospholipids are clinically tested materials with 
well-characterized safety profiles. Moreover, the manufacture of 
Fig. 7. TGF-NP treatment attenuates OA progression after DMM surgery in mice. (A) Immunostaining of p-EGFR 
in mouse knee cartilage at 1 month after sham or DMM surgery. In the DMM group, mice were divided into four 
groups receiving PBS, TGF-DBCO, Ctrl-NP, or TGF-NP intra-articular treatments. Scale bar, 100 m. n = 3 mice per 
group. (B) Safranin O/Fast Green staining of knee joints at the medial site at 2 and 3 months after surgery. Low: 
low-magnification image; high: high-magnification image of the yellow boxed area above. Scale bars, 200 m. (C) The 
OA severity of knee joints at 3 months after surgery measured by Mankin score. n = 8 mice per group. (D) Average 
uncalcified (Uncal. Th.) cartilage thickness of knee joints at 3 months after surgery was quantified. n = 8 mice 
per group. (E) Representative 3D color maps derived from microCT images showing SBP thickness (SBP Th.). Color 
ranges from 0 (blue) to 320 m (red). (F) SBP thickness at the medial posterior site of femoral condyle was calculated. 
n = 8 mice per group. (G) Hematoxylin and eosin staining of mouse knee joints focusing on synovium at 2 months 
after surgery. Red boxed areas indicate the synovial tissues. Scale bar, 200 m. (H) Synovitis score was measured. n = 8 
mice per group. (I) von Frey assay was performed at 0, 1, 2, 4, 8, and 12 weeks after surgery. n = 8 per group. Statistical 
analysis was performed using one-way ANOVA with Tukey’s post hoc analysis. Data are presented as means ± SEM. 
*P < 0.05, **P < 0.01, and ***P < 0.001 in (C), (D), (F), and (H). *P < 0.05, **P < 0.01, and ***P < 0.001 for DMM TGF-NP 
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these NPs is simple, reproducible, and scalable, which could allow 
fast translation into clinic use. We further used proximity-based 
sortase ligation to enable the highly efficient, site-specific bioconju-
gation of TGF onto our NPs. Currently, one of the greatest chal-
lenges in combining protein-based targeting ligands with NPs is the 
low efficiency of bioconjugation. To address this limitation, we used 
a new strategy that uses a unique sortase fusion protein for the effi-
cient and site-specific modification of the C terminus of recombi-
nant proteins. On the basis of this method, a DBCO moiety was 
ligated to the C terminus of TGF. The availability of the DBCO 
group, subsequently, allows for the facile bioconjugation of the 
TGF to azide-labeled NPs using highly efficient click chemistry. 
Last, the TGF-NPs exhibit therapeutic efficacy, with no detectable 
side effects on joint structure and peripheral organs. The TGF-NPs 
resolve the issues of short in vivo half-life and low cartilage penetra-
tion efficiency of free growth factors. Local delivery of TGF-NPs 
into knee joints after OA injury effectively attenuated cartilage 
degeneration and blocked SBP sclerosis and joint pain in mice, thus 
paving the way toward future translational studies that target EGFR 
signaling. We are aware that mouse articular cartilage is much thin-
ner than the human counterpart. Although our culture experiment 
suggests that TGF-NP can penetrate at least 1 mm into bovine car-
tilage, future studies are needed to optimize the nanoformulation to 
achieve better penetration in large-animal models before translat-
ing this approach into clinical applications.
Activation of EGFR signaling for OA treatment has several con-
cerns. It is well established that EGFR ligands, including TGF and 
HBEGF, reduce anabolic gene expression (Sox9, Col2a1, and Aggrecan) 
and increase catabolic gene expression (Mmp13) in cultured chon-
drocytes (30, 43). Our studies using chondroprogenitors derived 
from HBEGF OverCol2 articular cartilage showed decreased anabolic 
gene expression and Alcian blue staining when they underwent 
chondrogenic differentiation in vitro. However, these changes are 
relatively modest, and a considerable amount of cartilage matrix still 
remained in the pellet. Moreover, histology of adult HBEGF OverCol2 
knees revealed no change in type II and type X collagen and proteo-
glycan amounts, indicating that cell culture data might not be di-
rectly correlated to animal data. We also observed that MMP13 
expression was decreased in HBEGF OverCol2 chondrogenic culture 
but unchanged in the HBEGF OverCol2 joints. These data are contra-
dictory to a previous report that adding HBEGF to chondrocyte 
culture increases Mmp13 expression (44). We reason that HBEGF 
dosage and in vivo versus in vitro conditions might determine the 
final outcomes.
Several EGFR activation mouse models have been investigated 
for OA study. Most of them used Mig6 knockout models, all having 
elevated EGFR activity in the cartilage. The global ablation of Mig6 
causes severe joint deformity in young mice (45), whereas the cartilage- 
specific (Col2-Cre) and skeletal-specific (Prx1-Cre) knockout of 
Mig6 have much more minor joint phenotypes, with initial anabolic 
expansion of articular cartilage followed by modest degeneration or 
osteophyte formation at a later age (12, 13). Similar to our study, a 
previous report took advantage of DTR to construct Dermo1-Cre HBEGF 
(HBEGF OverDermo1) mice (46). At a young age, these mice develop 
chondrodysplasia, chondroma, OA-like joint defects, and bone pheno-
types. While Dermo1-Cre broadly targets mesenchymal lineage 
cells (47), the Col2-Cre (48) and Aggrecan-CreER (49) are more specific 
for cartilage tissue. Li et al. (46) also reported that Col2-Cre HBEGF 
mice have normal body weight and body size but slightly distorted 
knee joints. In our hands, HBEGF OverCol2 and OverAgcER mice do 
not show any joint deformity and bone abnormalities. Therefore, 
we propose that the therapeutic effect of EGFR signaling depends 
on its activity and specificity. Mig6 global knockout and HBEGF 
OverDermo1 mice have the highest EGFR activity not only in cartilage 
but also in other organs, thus tipping the balance more toward cat-
abolic actions on cartilage. Mig6 CKO mice have increased EGFR 
activity but not as high as the previous two models such that they 
exhibit anabolic actions first and then catabolic actions. In addition, 
we cannot rule out the possibility that Mig6 knockout mice have 
off-target effects because Mig6 also regulates signaling pathways 
other than EGFR, such as HGF/Met (50). Because of their cartilage 
and EGFR specificity, HBEGF OverCol2 and OverAgcER mouse mod-
els, as well as joint delivery of TGF-NPs, demonstrate that it is 
feasible to precisely control EGFR signaling for cartilage anabolic 
actions selectively without incurring undesired catabolic effects. 
These observations also suggest that future study of TGF-NPs 
should optimize dosage, duration, and ligand specificity to achieve 
the best therapeutic effects.
Initial findings revealed that TGF (30) and HBEGF (44) are el-
evated in degenerated OA cartilage. Accordingly, it was proposed 
that EGFR inhibitors could be repurposed for OA treatment. To 
date, the results of EGFR inhibitors on rodent OA progression are 
mixed and often contradictory, depending on the gender and type 
of inhibitors used in experiments (29). In our hands, we constantly 
observed accelerated OA by gefitinib treatment (25). Our previous 
study clearly showed that EGFR activity is most concentrated in the 
superficial layer of articular cartilage, which is drastically reduced 
during OA initiation (8). In this study, overactivation of EGFR in 
animal models, particularly using inducible Aggrecan-CreER or by 
TGF-NP injections, demonstrated that elevating EGFR activation 
at the early stage of OA was beneficial. We also provided evidence 
that TGF-NP treatment starting from 1 month after DMM sur-
gery remained effective. The underlying mechanisms, as shown 
here and in our previous studies, involve the protection of super-
ficial layer from OA-induced destruction. At a later stage when the 
superficial zone is disrupted and TGF and HBEGF are elevated, 
whether further increasing EGFR activity could still render a pro-
tective or even reparative effect on cartilage needs further investiga-
tion. During OA degeneration, new chondrocyte cell clusters are 
frequently formed under the damaged cartilage surface in an 
attempt to repair and regenerate (51). Those cell clusters are prolif-
erative with stem cell properties. However, under normal circum-
stances, impaired cartilage does not repair by itself. We speculate 
that as growth factors for mesenchymal progenitors, TGF and 
HBEGF are likely to be up-regulated for forming cell clusters after 
damage, yet their endogenous expression is not sufficiently high to 
regenerate the cartilage. Therefore, exogenous EGFR ligand might 
be helpful in attenuating OA progression even at a late stage.
One additional concern of our treatment approach is the possi-
ble carcinogenic effect of activating EGFR signaling. High EGFR 
activities due to missense mutations, deletions, and insertions are 
often observed in breast, lung, liver, brain tumors, etc. (52). In our 
study, we attempted to minimize this possibility by locally overacti-
vating EGFR in cartilage. No obvious changes were observed in vital 
internal organs in mice overexpressing HBEGF specifically in carti-
lage up to 12 months of age or in mice intra-articularly injected with 
TGF-NPs. However, long-term pharmacological assays should be 
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There is a great unmet medical need for a disease-modifying OA 
drug. In this study, we have demonstrated the feasibility of targeting 
EGFR signaling to block OA initiation and constructed a drug for 
such treatment without obvious side effects. This is just the initial 
step toward the translation of our findings into clinical usage. Be-
cause most patients with OA are already at middle or late OA stages, 
future experiments should test the efficacy of TGF-NPs after OA 
has well developed using large-animal models. Optimization of the 
structure of conjugates, likely using different EGFR ligands, and the 
dosage of conjugates should be explored to achieve favorable treat-
ment outcomes. Such comprehensive studies will shed light on 
developing disease-modifying drugs that benefit patients with OA.
MATERIALS AND METHODS
Study design
This study was performed to evaluate whether activating EGFR sig-
naling specifically in joint cartilage could protect articular cartilage 
from OA degeneration. This objective was addressed by (i) examin-
ing articular cartilage phenotype in HBEGF OverCol2 and HBEGF 
OverAgcER mice, (ii) delineating the cellular and molecular changes 
in their articular cartilage, (iii) characterizing their responses to-
ward OA surgery, (iv) synthesizing and characterizing TGF-NPs, 
and (v) studying the effect of intra-articular injection of TGF-NPs 
on attenuating OA progression. Sample size was determined by the 
investigators according to previous experimental experience. The 
exact n numbers used in each experiment are indicated in the re-
spective figure legends. For in vivo experiments, data from animals 
that died or had severe health problems during the experiments 
were excluded. Samples were assigned randomly to the experimen-
tal and control groups. Animal or sample allocation and data acqui-
sition in vivo or ex vivo were performed in a blinded manner. The 
investigators were not blinded during data analysis.
Animals
All animal work performed in this study was approved by the Insti-
tutional Animal Care and Use Committee at the University of 
Pennsylvania. In accordance with the standards for animal housing, 
mice were group housed at 23° to 25°C with a 12-hour light/dark cycle 
and allowed free access to water and standard laboratory pellets.
Col2-Cre mice or Aggrecan-CreER mice were bred with Rosa-DTR 
mice to generate Col2-Cre DTR (HBEGF OverCol2) and Aggrecan-CreER 
DTR (HBEGF OverAgcER) mice, respectively, and their WT (DTR- or 
Cre-only) siblings. All mouse lines were purchased from the Jackson 
laboratory.
To induce OA, male mice 3 months of age were subjected to 
DMM surgery or sham surgery at right knees as described previously 
(25). Briefly, in DMM surgery, the joint capsule was opened imme-
diately after anesthesia, and the medial meniscotibial ligament was 
cut to destabilize the meniscus without damaging other tissues. In 
sham surgery, the joint capsule was opened in the same fashion but 
without any further damage.
HBEGF OverAgcER mice and WT controls received tamoxifen (Sigma- 
Aldrich) injections (75 mg/kg per day) for 5 days before DMM sur-
gery at 3 months of age. For the EGFR inhibitor treatment study, 
these mice additionally received vehicle (0.5% methyl cellulose) 
or gefitinib (100 mg/kg; LC Laboratories) via oral gavage once every 
other day for 8 weeks after surgery. For EdU incorporation study, 
3-day-old mice received intraperitoneal injections of EdU (2.5 mg/kg; 
Thermo Fisher Scientific) for 4 days. Knee joints were harvested on 
the fifth day or 3 weeks later.
For the TGF-NP treatment study, male C57Bl/6 mice (the Jackson 
laboratory) were randomly divided into five groups: sham surgery 
(sham), DMM and PBS treatment, DMM and free TGF–DBCO 
treatment (TGF-DBCO), DMM and Ctrl-NP treatment (Ctrl-NP), 
and DMM and TGF-NP treatment (TGF-NP). Treatments were 
given by intra-articular injection of 10 l of PBS, TGF-DBCO 
(10 M TGF content), Ctrl-NPs (NP with no TGF conjugation), 
or TGF-NPs (10 M TGF content) once every 3 weeks initiated 
immediately after DMM surgery. Mice were euthanized 2 months 
after surgery (receiving a total number of three injections) or 3 months 
after surgery (receiving four injections).
TGF-NP synthesis
TGF-NPs were prepared via click reaction (27). Briefly, stock 
solutions of poly(ethylene glycol) (4000)–polycaprolactone (3000) 
copolymer (denoted as PEG-PCL; Polymer Source), polylysine 
(3300)–polycaprolactone (4000) copolymer (denoted PLL-PCL), and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene 
glycol)-5000] (ammonium salt) (denoted as DSPE-PEG5K-N3; 
Avanti Polar Lipids Inc) in chloroform (Sigma-Aldrich) were mixed in 
the following molar ratios: PEG-PCL/PLL-PCL/DSPE-PEG5K-N3 
(55/20/25). The total amount of PEG-PCL for each of the NP com-
positions was 1 mg. The chloroform was removed using a direct 
stream of nitrogen before vacuum desiccation for overnight. NPs 
were formed by adding an aqueous solution (0.1 M PBS, pH 7.4) to 
the dried film and incubating in a 60°C water bath for 3 min and 
then sonicating for another 3 min at the same temperature. To pre-
pare TGF-NPs, azide-modified NPs were mixed with TGF-DBCO 
at a molar ratio of 1 to 1  in 0.1 M PBS (pH 7.4). Reactions were 
mixed overnight at room temperature and then purified by centrif-
ugal filter devices (Amicon Ultra-4, 50K MWCO, Millipore Corp.). 
Samples were stored in the dark at 4°C.
Cartilage explant, cell culture, immunoblotting, and  
real-time reverse transcription PCR analysis
Chondroprogenitors were harvested from articular cartilage of 
5-month-old mouse knee joints. Briefly, cartilage was peeled from 
femoral condyles and tibial plateau by sterile scalpel under dissec-
tion microscope and incubated in 0.25% trypsin (Invitrogen) for 
1 hour, followed by 2 hours of digestion with type I collagenase 
(900 U/ml; Worthington Biochemical). Dissociated cells from the 
second digestion were cultured in Gibco Dulbecco’s modified Eagle’s 
medium (DMEM) medium containing 10% fetal bovine serum 
(FBS), streptomycin (100 g/ml), and penicillin (100 U/ml). For 
CFU-F assay, 1 × 104 cells were seeded in a six-well plate and cul-
tured for 7 days followed by crystal violet staining. CFU number 
was counted under microscope. For proliferation assay, cells were 
seeded in culture medium. Cell counting was performed on the in-
dicated days. For apoptosis assay, cells at 40 to 60% confluency were 
serum starved overnight and then pretreated with either vehicle or 
TNF (25 ng/ml; Pepro-Tech). Two days later, apoptotic cells were 
quantified using ethidium bromide (5 mg/ml; Sigma-Aldrich) and 
acridine orange (5 mg/ml; Thermo Fisher Scientific) staining as 
described previously (53). For chondrogenic differentiation assay, 
confluent cells were cultured in differentiation medium [DMEM, strep-
tomycin (100 g/ml), penicillin(100 U/ml), 1% insulin-transferrin- 
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dexamethasone, sodium pyruvate (100 g/ml), ascorbate 2-phosphate 
(50 g/ml), and TGF3 (10 ng/ml)]. Media were changed twice a week.
Synovial mesenchymal progenitors were harvested from 5-month- 
old mouse knee joints as described previously with minor modifica-
tions (54). Briefly, the quadricep reversing approach was used to 
harvest mouse synovium, which was then incubated in 0.25% trypsin 
for 0.5 hours, followed by 1-hour digestion with type I collagenase 
(300 U/ml). Dissociated cells from the second digestion were cul-
tured in DMEM medium containing 10% FBS, streptomycin (100 g/ml), 
and penicillin (100 U/ml). For CFU-F assay, 4 × 103 cells were seeded 
in a six-well plate and cultured for 10 days followed by crystal violet 
staining. CFU-F number was counted under microscope.
Human articular cartilage was prepared from the deidentified 
specimens obtained at the total arthroplasty of the knee joints. 
Explants were harvested from femoral condyle area with normal 
cartilage morphology using biopsy punch (3 mm in diameter and 
2 mm in thickness) and cultured in chemically defined medium 
[DMEM, streptomycin (100 g/ml), penicillin (100 U/ml), 1% ITS+ 
Premix, l-proline (40 g/ml), 0.1 M dexamethasone, sodium pyru-
vate (100 g/ml), and ascorbate 2-phosphate (50 g/ml)] in a 48-well 
plate. TGF-NPs were added to the medium with a final TGF con-
centration of 100 ng/ml. After 4 days of incubation with a medium 
change on day 3, cartilage explants were washed three times with PBS 
and processed either for RNA extraction or for paraffin sectioning.
To perform Western blot, cell lysate was solubilized in radio-
immunoprecipitation assay buffer [50 mM tris (pH 7.4), 100 mM 
NaCl, 1% sodium deoxycholate, 1% Triton X-100, and 0.1% SDS] 
with protease inhibitor (Sigma-Aldrich). Cell lysate (50 mg) was 
separated by SDS–polyacrylamide gel electrophoresis (Bio-Rad) 
and transferred onto polyvinylidene difluoride (Bio-Rad) mem-
brane. Immunoreactive protein bands were visualized using rabbit 
primary antibodies against EGFR (1:1000; CST, 4267), p-EGFR 
(1:1000; Abcam, ab40815), ERK (1:1000; CST, 4695), p-ERK (1:1000; 
CST, 4370), HBEGF/DTR (1:1000; Novus Biologicals, AF8239), 
-Actin (1:3000; CST, 4970), and secondary antibodies (Vector Lab-
oratories), followed by chemiluminescence (Amersham ECL Western 
Blotting Detection Reagents, GE Healthcare).
RNA was harvested from chondrocyte culture using Tri Reagent 
(Sigma-Aldrich). TaqMan Reverse Transcription kit (Applied Bio-
systems) was used to reverse transcribe mRNA into complementary 
DNA. After this, polymerase chain reaction (PCR) was performed 
using a Power SYBR Green PCR Master Mix kit (Applied Biosystems). 
The primer sequences for the genes used in this study are listed in 
table S1.
Statistical analysis
Data are expressed as means ± SEM and analyzed by t tests, one-
way analysis of variance (ANOVA) with Dunnett’s or Tukey’s 
posttest, and two-way ANOVA with Bonferroni’s or Tukey’s posttest 
for multiple comparisons using Prism 8 software (GraphPad Soft-
ware). For cell culture experiments, observations were repeated in-
dependently at least three times with a similar conclusion, and only 
data from a representative experiment are presented. Values of 




Fig. S1. HBEGF OverCol2 mice have normal body weight and body length.
Fig. S2. HBEGF OverCol2 mice overexpress HBEGF in cartilage.
Fig. S3. HBEGF OverCol2 mice have normal joint structure.
Fig. S4. Overexpressing HBEGF in articular cartilage does not affect long bone structure.
Fig. S5. Mesenchymal progenitors in synovium are not affected by HBEGF overexpression in 
cartilage.
Fig. S6. Overexpressing HBEGF in cartilage does not affect cartilage matrix composition and 
cartilage degradation.
Fig. S7. Overexpressing HBEGF in cartilage does not affect vital internal organs.
Fig. S8. HBEGF OverAgcER mice have increased HBEGF expression and EGFR activity in knee 
articular cartilage.
Fig. S9. Synthesis and characterization of PLL-PCL.
Fig. S10. TGF-NPs result in similar morphology changes in chondrocytes as free TGF.
Fig. S11. TGF-NPs are functional on human articular cartilage.
Fig. S12. TGF-NPs doped with PLL-PCL enhance bovine cartilage uptake.
Fig. S13. TGF-NPs doped with PLL-PCL improve their penetration and retention in bovine 
cartilage tissue.
Fig. S14. Biodistribution of TGF-NPs within the knee joints and some major organs.
Fig. S15. TGF-NP treatment attenuates OA progression after DMM surgery in mice.
Fig. S16. TGF-NP treatment starting at 1 month after DMM attenuates further OA progression.
Fig. S17. The mechanism underlying the protective action of EGFR overactivation on articular 
cartilage after DMM surgery.
Fig. S18. Intra-articular injections of TGF-NPs for 2 months do not affect vital internal organs 
and gross joint morphology.
Table S1. Mouse real-time PCR primer sequences.
Data file S1. Individual subject-level data (Excel file).
Data file S2. Western blotting films (PDF).
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